Laura M. Kohtamaki
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Intra-patient evolution of tumor microenvironment in the pathogenesis of treatment-naïve metastatic melanoma patients.
Journal: Acta oncologica (Stockholm, Sweden)
Published: August 25, 2023
Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.
Journal: Clinical lung cancer
Published: November 10, 2022
Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Journal: Acta oncologica (Stockholm, Sweden)
Published: October 29, 2022
High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma.
Journal: Translational oncology
Published: September 17, 2021
Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
Journal: Melanoma research
Published: June 16, 2021
BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients.
Journal: Melanoma research
Published: March 06, 2021
Limited-duration anti-PD-1 therapy for patients with metastatic melanoma.
Journal: Acta oncologica (Stockholm, Sweden)
Published: February 01, 2020
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
Journal: Acta oncologica (Stockholm, Sweden)
Published: October 01, 2019
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Journal: Cancer immunology, immunotherapy : CII
Published: August 20, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026